1. CV Risk Doesn't End in the Cath Lab

3. Program Themes

4. Adjusted Risk of All-Cause Death in Post-MI Survivors

5. Primary Efficacy Endpoint Over Time (PLATO) Composite of CV Death, MI, or Stroke

6. Primary Endpoint Through Follow-Up in the SOLID-TIMI 52 Trial

7. 68-Year-Old Man: STEMI Treated With BMS

8. Thrombotic vs Bleeding Risk

9. Patients Outcomes After Recent Index MI or ADP Blocker Discontinuation

10. Case 2: 74-Year-Old Woman With NSTEMI

11. Case 2: Discharge Medications

12. Intensification of Lipid Therapy?

13. Additional Risk Factors to Consider

14. Bleeding Risk Associated With Elevated GDF-15 in Ticagrelor vs Placebo-Treated Patients in PEGASUS

15. Reasons for and Implications of Elevated GDF-15 Level

16. Increased Ischemic Risk Identified: What to Consider?

17. COMPASS: Primary Endpoint* Rivaroxaban Plus Aspirin vs Aspirin Alone

18. COMPASS: Additional Outcomes

19. EUCLID Subgroup: Prior Revascularization

20. PEGASUS: PAD Subgroup

21. Anti-inflammatory Therapy as Secondary CVD Prevention

22. Case 3: 58-Year-Old Man With STEMI

23. Back to Basics: Adherence to Evidence-Based Strategies

24. LDL-C Reduction: Evidence Points to Lowest Is Best

25. Effects of Adding Anacetrapib to Intensive Statin Therapy

26. Cost-Effectiveness Associated With Emerging Strategies

27. Concluding Comments

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)